South African Tuberculosis Vaccine Initiative (SATVI)

The South African Tuberculosis Vaccine Initiative (SATVI) is a tuberculosis research group with a research focus that spans several disciplines including paediatrics, infectious diseases, epidemiology, public health, immunology, systems biology and clinical sciences. SATVI has a large and well-developed clinical field site in the Boland Overberg region, with the core on the premises of the Brewelskloof TB Hospital in Worcester, from where most clinical/epidemiological studies and clinical trials of new TB vaccines are conducted. The Immunology and Laboratory based work is led by Associate Professor Tom Scriba; and the Clinical Trials work is led by SATVI Director, Associate Professor Mark...

South african tuberculosis vaccine initiative (satvi) operates in the Research services industry.

South african tuberculosis vaccine initiative (satvi)'s revenue is 11m - 100m

South african tuberculosis vaccine initiative (satvi) has 51 - 200 employees.